Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chrysiis Michaloglou

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Genes & Development|November 17, 2010
The essence of senescenceThomas Kuilman, Chrysiis Michaloglou, Wolter J Mooi, et al.
Cell|June 17, 2008
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory networkThomas Kuilman, Chrysiis Michaloglou, Liesbeth C W Vredeveld, et al.
Genes & Development|May 3, 2012
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesisLiesbeth C W Vredeveld, Patricia A Possik, Marjon A Smit, et al.
Nature|August 5, 2005
BRAFE600-associated senescence-like cell cycle arrest of human naeviChrysiis Michaloglou, Liesbeth C W Vredeveld, Maria S Soengas, et al.
Molecular Cancer Therapeutics|February 28, 2018
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast CancerChrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, et al.
NAR Cancer|October 9, 2025
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repairGiuditta Illuzzi, Alessandro Galbiati, Anna D Staniszewska, et al.
Oncoimmunology|June 27, 2022
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumorsAnna D Staniszewska, Joshua Armenia, Matthew King, et al.
Plos One|April 25, 2013
The tyrosine phosphatase PTPN14 is a negative regulator of YAP activityChrysiis Michaloglou, Waltraut Lehmann, Typhaine Martin, et al.
Journal of Medicinal Chemistry|July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate CancerSharan K Bagal, Peter C Astles, Coura Diène, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Genes & Development|November 17, 2010
The essence of senescenceThomas Kuilman, Chrysiis Michaloglou, Wolter J Mooi, et al.
Cell|June 17, 2008
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory networkThomas Kuilman, Chrysiis Michaloglou, Liesbeth C W Vredeveld, et al.
Genes & Development|May 3, 2012
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesisLiesbeth C W Vredeveld, Patricia A Possik, Marjon A Smit, et al.
Nature|August 5, 2005
BRAFE600-associated senescence-like cell cycle arrest of human naeviChrysiis Michaloglou, Liesbeth C W Vredeveld, Maria S Soengas, et al.
Molecular Cancer Therapeutics|February 28, 2018
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast CancerChrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, et al.
NAR Cancer|October 9, 2025
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repairGiuditta Illuzzi, Alessandro Galbiati, Anna D Staniszewska, et al.
Oncoimmunology|June 27, 2022
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumorsAnna D Staniszewska, Joshua Armenia, Matthew King, et al.
Plos One|April 25, 2013
The tyrosine phosphatase PTPN14 is a negative regulator of YAP activityChrysiis Michaloglou, Waltraut Lehmann, Typhaine Martin, et al.
Journal of Medicinal Chemistry|July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate CancerSharan K Bagal, Peter C Astles, Coura Diène, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Pageof 1